LOS ANGELES, Nov. 4, 2012 (GLOBE NEWSWIRE) -- As of 3:20 p.m. PT/6:20 p.m. ET on Sunday, Nov. 4, 2012, the American Heart Association has lifted the embargo on its news release on the "Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal management of Multivessel disease" (FREEDOM) trial, which had been embargoed until 4:58 p.m. PT/7:58 p.m. ET on Sunday, Nov. 4, 2012. The release was inadvertently sent out over the national wire by the association's vendor GlobeNewswire.
The AHA would like to thank the news media who continue to abide by our embargo policy.
For Media Inquiries:
AHA News Media Office, Nov. 3-7,
at the Los Angeles Convention Center: (213) 743-6205
For Public Inquiries: (800) AHA-USA1 (242-8721)
heart.org and strokeassociation.org
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.